Abstract:Importance Intrathoracic progression remains the predominant pattern of failure in patients treated with concurrent chemoradiation followed by a consolidation immune checkpoint inhibitor for locally advanced, unresectable non–small cell lung cancer (NSCLC). Objective To determine the maximum tolerated dose (MTD) and use of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost. Design, Setting, and Participants This was an early-phase, single-institution, radiation dose-escalation nonrandomized controlled trial with concurrent chemotherapy among patients with clinical stage II (inoperable/patient refusal of surgery) or III NSCLC ( American Joint Committee on Cancer Staging Manual, seventh edition ). Patients were enrolled and treated from May 2011 to May 2018, with a median patient follow-up of 18.2 months. Patients advanced to a higher SABR boost dose if dose-limiting toxic effects (any grade 3 or higher pulmonary, gastrointestinal, or cardiac toxic effects, or any nonhematologic grade 4 or higher toxic effects) occurred in fewer than 33% of the boost cohort within 90 days of follow-up. The current analyses were conducted from January to September 2023. Intervention All patients first received 4 Gy × 10 fractions followed by an adaptive SABR boost to residual metabolically active disease, consisting of an additional 25 Gy (low, 5 Gy × 5 fractions), 30 Gy (intermediate, 6 Gy × 5 fractions), or 35 Gy (high, 7 Gy × 5 fractions) with concurrent weekly carboplatin/paclitaxel. Main Outcome and Measure The primary outcome was to determine the MTD. Results Data from 28 patients (median [range] age, 70 [51-88] years; 16 [57%] male; 24 [86%] with stage III disease) enrolled across the low- (n = 10), intermediate- (n = 9), and high- (n = 9) dose cohorts were evaluated. The protocol-specified MTD was not exceeded. The incidences of nonhematologic acute and late (&gt;90 days) grade 3 or higher toxic effects were 11% and 7%, respectively. No grade 3 toxic effects were observed in the intermediate-dose boost cohort. Two deaths occurred in the high-dose cohort. Two-year local control was 74.1%, 85.7%, and 100.0% for the low-, intermediate-, and high-dose cohorts, respectively. Two-year overall survival was 30.0%, 76.2%, and 55.6% for the low-, intermediate-, and high-dose cohorts, respectively. Conclusions and Relevance This early-phase, dose-escalation nonrandomized controlled trial showed that concurrent chemoradiation with an adaptive SABR boost to 70 Gy in 15 fractions with concurrent chemotherapy is a safe and effective regimen for patients with locally advanced, unresectable NSCLC. Trial Registration ClinicalTrials.gov Identifier: NCT01345851

The potential of integrating stereotactic ablative radiotherapy techniques with hyperfractionation for lung cancer

Alternating Expiration and Inspiration Breath-Hold Spares the Chest Wall During Stereotactic Body Radiation Therapy for Peripheral Lung Malignancies.

Impact Of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy And Vmat Delivery For Prostate Cancer

T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer

Estimation of the Effect of Target and Normal Tissue Sparing Based on Equivalent Uniform Dose-Based Optimization in Hypofractionated Radiotherapy for Lung Cancer

Dosimetric Comparison of 192ir Sources Stereotactic Ablative Brachytherapy by Coplanar Template Assisted CT Guidance and Stereotactic Body Radiation Therapy in the Treatment of Early Stage Lung Cancer

Hypofractionated 192ir Source Stereotactic Ablative Brachytherapy with Coplanar Template Assistance in the Primary Treatment of Peripheral Lung Cancer.

Clinical and Radiobiologic Effect of Partial Stereotactic Ablative Radiation Therapy in NSCLC

Is it necessary to prescribe the same dose to subclinical lesions as gross tumor volume in non-small-cell lung cancer? —a failure pattern analysis

Clinical Outcome of CT-Guided Stereotactic Ablative Brachytherapy for Unresectable Early Non-Small Cell Lung Cancer: A Retrospective, Multicenter Study

Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early‐stage non‐small‐cell lung cancer: a population‐based study

Using 4DCBCT simulation and guidance to evaluate inter-fractional tumor variance during SABR for lung tumor within the lower lobe

Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT

Dosimetry Study of Fourtypes of Radiotherapy Plan Optimization Methods in the Hypofractionated Radiotherapy for Lung Cancer

Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer

Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma

Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma

Efficacy of Template-Assisted Neoadjuvant 192ir Hypofractionated Stereotactic Ablative Brachytherapy in Resectable Non-Small Cell Lung Cancer

Proton Improves BED&nbsp;Compared With Photon Beam-based Partial Stereotactic Ablative Boost Radiotherapy for Large Non-small Cell Lung Cancer

Biologically Effective Dose-response Relationship for Patients with Limited-stage Small-cell Lung Cancer Treated with Combined Radiotherapy and Chemotherapy

Variability of Α/β Ratios for Prostate Cancer with the Fractionation Schedule: Caution Against Using the Linear-Quadratic Model for Hypofractionated Radiotherapy